Evidence for Influenza and RSV interaction from 10 years of enhanced surveillance in Nha Trang, Vietnam, a modelling study.

Authors: Naomi R Waterlow¹, Michiko Toizumi^{2,3}, Edwin van Leeuwen^{1,4}, Hien-Anh Thi Nguyen⁵, Lay Myint-Yoshida^{2,3*}, Rosalind M Eggo^{1*}, Stefan Flasche^{1*}.

Affiliations:

¹ Centre for Mathematical Modeling of Infectious Disease, London School of Hygiene and Tropical Medicine, UK

² Department of Pediatrics, Nagasaki University Hospital, Nagasaki University, Nagasaki 852-8102, Japan

³ Department of Pediatric Infectious Diseases, Institute of Tropical Medicine, Nagasaki University, Nagasaki 852-8523, Japan

⁴ Statistics, Modelling and Economics Department, UKHSA

⁵ National Institute of Hygiene and Epidemiology, Hanoi, Vietnam

* These authors have contributed equally

Conflicts: None

Funding: NRW was supported by the Medical Research Council (grant number [MR/N013638/1](#)). EvL and RME declare funding from the National Institute for Health Research (NIHR) Health Protection Research Unit (HPRU) in Modelling and Health Economics, a partnership between PHE, Imperial College London, and LSHTM (grant number NIHR200908). EvL was supported by the European Union's Horizon 2020 research and innovation programme - project EpiPose (101003688). SF is funded through a Sir Henry Dale Fellowship jointly funded by the Wellcome Trust and the Royal Society (grant number [208812/Z/17/Z](#)). RME acknowledges an HDR UK Innovation Fellowship (grant: MR/S003975/1), MRC (grant: MC_PC 19065), and NIHR (grant: NIHR200908) for the Health Protection Research Unit in Modelling and Economics at LSHTM. The views expressed in this publication are those of the author(s) and not necessarily those of the funders. This ARI surveillance study in Nha Trang was supported by Japan Program for Infectious Diseases Research and Infrastructure, Japan Agency for Medical Research and Development (AMED) under Grant Number JP21wm0125006.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

Abstract: Influenza and Respiratory Syncytial Virus (RSV) interact within their host posing the concern for heterologous ecological changes following vaccination. We aimed to estimate the population level impact of their interaction.

We developed a dynamic age-stratified two-pathogen mathematical model that includes pathogen interaction through competition for infection and enhanced severity of dual infections. We used parallel tempering to fit its parameters to 11 years of enhanced hospital-based surveillance for acute respiratory illnesses (ARI) in children under 5 years old in Nha Trang, Vietnam.

The data supported either a 41% (95%CrI: 36 - 54) reduction in heterologous acquisition during infection and for 10.0 days (95%CrI 7.1 -12.8) thereafter, or no cross protection. We estimate that co-infection increased the probability for an infection in <2y old children to be reported 7.2 fold (95%CrI 5.0 - 11.4); or 16.6 fold (95%CrI 14.5 - 18.4) in the respective scenarios. Absence of either pathogen was not to the detriment of the other.

We find stronger evidence for severity enhancing than for acquisition limiting interaction. In this setting vaccination against either pathogen is unlikely to have a major detrimental effect on the burden of disease caused by the other.

Introduction

Influenza and Respiratory Syncytial Virus (RSV) have large health and economic impacts globally, particularly in young children where they cause 870 000¹ and 3.2 million² hospitalisations in <5 year olds per year respectively. While pediatric influenza vaccines are licensed for use in some countries, global uptake is poor and efficacy depending on the match to the circulating strains. RSV vaccines are in development, with close to 20 vaccine candidates being evaluated in pre-licensure trials³.

The impact of vaccination may be enhanced if co-infections increase the propensity of severe disease beyond that of either pathogen⁴. However, the impact of vaccination may be lessened if vaccination reduces competitive pressure between influenza and RSV and thus leads to increased circulation of the other pathogen. Such competitive pressure has been observed in the form of cross protection in mouse studies that showed e.g. a protective effect of live attenuated influenza vaccine administration on RSV replication⁵ and influenza infection on RSV severity⁶, mediated by the innate immune system. Population level evidence for the effect of cross-protection on influenza and RSV epidemiology, however, is largely of observational nature: a lack of coincidence in peak timings^{7,8}, changes in RSV peak timing following unusual influenza seasons^{9–14} and alternating infection patterns¹⁵.

Cross-protection could occur through a variety of mechanisms including viral competition for resources in the host¹⁶, the activation of the innate immune system such as through toll-like receptors (TLRs) 3 and 7^{17,18} or short term immune memory through surviving cells in an antiviral state (e.g. epithelial cells following influenza infection¹⁹). Estimates of the duration of cross-protection and its biological pathway vary. Experimental infection of ferrets estimated less than 2 weeks protection between influenza A and B viruses²⁰, yet cells forming

the respiratory epithelium can survive in a state of heightened antiviral activation for 3 to 12 weeks after influenza A infection, with waning of the conferred protection observable at 6 weeks¹⁹.

In Nha Trang, Vietnam, for more than 10 years children admitted to the single public hospital with acute respiratory illness have been tested for presence of influenza and RSV infection as part of an enhanced surveillance. RSV circulation is highly seasonal, and influenza circulation varies year on year, thus giving a unique opportunity to systematically investigate evidence for their interaction at population level. We use this data in combination with a dynamic transmission model to estimate the strength of influenza and RSV competition and its effects on respiratory viral circulation.

Results

Descriptive Analysis

A total of 788 influenza and 1687 RSV hospitalised paediatric ARI cases were reported between 5th February 2007 and 4th December 2017; 78 (9% of influenza cases and 4% of RSV cases) of these were dual infections (Figure 1A&B). The mean age of at admission was 22 months and 16 months for influenza and RSV cases respectively. RSV notifications showed strong consistent seasonality across years, peaking usually in the 34th week of the year, whereas influenza showed less seasonality, but typically occurs after Tết Nguyên Đán holidays and before the RSV epidemic (Figure 1C).

There was a small, not statistically significant, negative correlation between weekly influenza and RSV incidence, with the Pearson correlation coefficient -0.074 (95% CrI: -0.160 to 0.009). (Figure S1)

We estimated that in order to observe the weekly reported number of dual infections when assuming independence of influenza and RSV infection, the annual RSV attack rate needed to be 720% (95% CrI: 560 - 1000) in ages 0-1y and 430% (95% CrI: 270 - 980) in ages 2-4y. The high attack rate suggests that in fact influenza and RSV infections are not independent but that co-infection is likely to substantially enhance the propensity for hospitalisation with ARI in this setting.

Figure 1: Data. A) Weekly reported infections of children under 5 years old infected with influenza and RSV over the study period. B) Total number of cases reported over the entire study period by age group and virus. C) Percentage of reported cases by week of the year for RSV and Influenza. The thick lines show the combined total reported across all years, the semi-transparent lines show the 4-week moving average per year.

Model inference

We developed an age-stratified two-pathogen mathematical model including pathogen interaction (competition for acquisition and increased disease propensity during dual infection), which was able to fit the case data for influenza and RSV well (Figure 2A, see supplement section 7 for further fitting and convergence details). The posterior estimates for the relative reduction in heterologous acquisition rates during and following Influenza or RSV infection was bimodal, with one mode at 0.004 (95%CrI 0.000 - 0.046), indicating hardly any competition for infection, and one mode at 0.41 (95%CrI 0.36 - 0.54), indicating moderate competition, assuming a cut-off between modes at 0.2 (Figure 2B). The posterior for the duration of interaction also had multiple modes, with the mode corresponding to moderate competition at 10.0 days (95%CrI 7.1 -12.8 days).

The main differences between modes for other parameters were in the detection rate of influenza, which ranged from 13 to 21% of infections reported (supplement section 8) and the increased reporting for dual infections. We estimate that in the moderate competition mode the observation of influenza and RSV coinfection among ARI cases was 8.2 (95%CrI 6.9 - 9.9) times more likely than would have been expected by chance in ages 2-4 and 16.6 (95%CrI 14.5 - 18.4) in ages 0-1. This compares to the no competition scenario where the observation of influenza and RSV coinfection among ARI cases was 3.6 (95%CrI 2.5 - 5.8) and 7.2 (95%CrI 5.0 - 11.4) times more likely than would have been expected by chance in ages 2-4 and 0-1 respectively.

To assess the relevance of RSV and influenza interaction on population level in this setting we simulated single pathogen versions of the parameterised model. In the case of no competition, absence of influenza (e.g. through widespread vaccination) reduced RSV

hospitalisations by 4.1% (95%CrI 3.3 - 7.1%) due to a lack of co-infections with higher propensity for severe disease and absence of RSV reduced influenza hospitalisations by 7.2% (95%CrI 4.4-7.2%) in the study period. In the moderate competition mode, absence of influenza reduced RSV hospitalisations by 5.7% (95%CrI 4.9 - 6.5%) . In the absence of RSV 1.8% (95%CrI -0.7 - 7.2%) more hospitalised cases for influenza occurred (Figure 2E).

Figure 2: Model. A) Model Fit: Black lines are the data, coloured lines are the 95% CrI posterior predictive interval and the mean. Panels show the fit by age group and Virus. B) Posterior estimates for parameters sigma and rho, and the corresponding likelihood values. Colour is split by sigma value of 0.2. C) Model Diagram. Individuals can be Susceptible (S), Exposed (E), Infectious (I) or Recovered (R) to Influenza (INF) or Respiratory Syncytial Virus (RSV). Following infection, (at rates λ_{INF} and λ_{RSV}), infectiousness wanes at a constant rate (γ_{INF} and γ_{RSV}), and the population enters the P state. Here they are immune to the virus they were infected by and cross-protected from the other (at strength σ). This protection wanes at rate ρ , and the

population enters the R compartment. In the R compartment the population is immune to the virus it was infected by, but not the other virus. Compartments $I_{RSV,i}P_{INF,i}$ and $I_{RSV,i}R_{INF,i}$ were combined, and $P_{RSV,i}I_{INF,i}$ and $R_{RSV,i}I_{INF,i}$ were combined, because they are effectively identical. Age susceptibility to RSV infection (τ_i). For clarity, age structure is given only by the subscript (i). D) Goodness of Fit: Observed cases by season against Modelled cases by season by virus and age group. The black line indicates the same value. E) Elimination scenarios: Number of cases modelled over all seasons, with different vaccination assumptions. Dots represent the median and lines the 95%CrI.

Sensitivity

As a sensitivity analysis, we assumed that co-infection will not modulate the propensity to be admitted to the local hospital with ARI symptoms (see supplement section 9), which pushed the posterior to the no competition mode. Further, we reran the model with a prior for strong competition through cross-protection, which pushed the posterior to the moderate interaction mode (see supplement section 10).

Discussion

We use data from more than 10 years of enhanced surveillance in Nha Trang, Vietnam to estimate the interaction of influenza and RSV epidemiology. We find that the observed data is consistent with infection reducing heterologous acquisition either by 41% (95%CrI 36% - 54%) for 10.0 days (95%CrI 7.1 -12.8 days) after infection or hardly at all. We estimate that influenza-RSV co-infection increases the propensity of an infection to be reported through the ARI hospital surveillance by between 2.5 and 18.4 times. We go on to show that control of one virus in this setting may have little impact on the circulation of the other, but can have an added benefit in reducing hospitalisations with co-infections.

A key strength of this dataset is the inclusion of cases infected with both influenza and RSV. Surprisingly though, some dual infections are reported at times when the two viruses seldom found in the hospital setting individually which may be a result of stochastic effect owing to the low number of observed dual infections and has limited the strength of inference from them. While many papers reporting co-infections do not include timings of the co-infections²¹⁻²³, these off-peak co-infections were not observed in Texas²⁴. In addition, in Nha Trang influenza circulates continuously at low prevalence with small epidemics, which would result in constant low-level cross-protection, rather than a short-term more concentrated interaction after a large epidemic, such as in the UK²⁵. This low-level cross-protection could have been absorbed into the transmission rate of RSV, explaining the low estimate of the RSV R_0 (1.24 compared to a range of 1.2 - 9.1 in published papers²⁶). These location-specific features will need to be considered when generalising the findings.

Much of the evidence for cross-protection is on an individual, biological level^{5,6,20}. However the impact of this individual level cross-protection on population level has been unclear, due to relatively small infection prevalence at any point in time (we estimate the seasonal attack rate for influenza as 0.011 - 0.15, and that peak prevalence never exceeded 0.8%), and thus a low propensity for co-infection with RSV. This may be exaggerated by clustering factors such as household transmission, reducing the opportunity for cross-infection. As an example in Kilifi, Kenya, household transmission of RSV contributed about 50% of all RSV transmission in households with young children²⁷. Our model assumes a well-mixed population, so does not account for any population clustering beyond the age-specific contact matrices. In addition, we assume that risk of infection is age-dependent, but otherwise homogeneous. However, increased risk of influenza infection may be correlated with

increased risk of RSV infection, due to demographic factors such as poor hygiene and household clustering. This may overestimate the effect of dual infections on reporting.

Evidence of cross-protection between influenza and RSV also comes from shifts in epidemic peaks, particularly after the 2009 influenza pandemic^{10–13}. However these studies are observational, and cannot test mechanisms. As the SARS-CoV-2 pandemic has demonstrated, behavioural responses can have huge impacts on viral circulation, with many geographies seeing shifts in epidemic peaks for usually consistent viruses, such as RSV^{28,29}, due to limitations on social contacts. Fear generated from high infection rates can also drastically alter individuals behaviour³⁰, even without wide-spread implementations of restrictions.

Our model does not take into account different subtypes of influenza or RSV, due to the added complexity, additional parameters required and the lack of subtype specific data. We therefore assume that any cross-protection between influenza and RSV does not vary by subtype. We account for different immunity levels to circulating influenza subtypes by fitting a susceptibility parameter at the start of each season. This is necessary because we fit to each season, rather than including immunity waning and fitting over the time period combined. While the start weeks of our season are fixed manually, we account for any impacts of this by fitting the proportion infected at the start of each season for each virus. While most of the posterior estimates are reasonable, the reporting rate for influenza infections is high, between 13 and 21%, compared to estimated 12% from data in Yoshida *et al.* (2013). However, many milder cases (including outpatients) are included in the reports as they may seek healthcare at the hospital, thereby increasing the expected reporting rate in this context. Overall therefore, our model estimates fit the data well, as well as known aspects of influenza and RSV

transmission, such as high influenza attack rates in children^{31,32}, and higher RSV severity in the youngest children³³.

In summary, we use a novel modelling framework to interrogate a unique case time-series for single and dual infection from Nha Trang, Vietnam. We find that influenza and RSV co-infection substantially increases hospitalisation rates in children. In addition we show that the data supports either no or moderate individual-level cross protection against infection but either way with relatively little population level impact. This alleviates some concerns of heterologous effects of RSV or influenza vaccination, however, particularly in settings with more pronounced and overlapping RSV and influenza seasons the impact of vaccination on the other pathogen's epidemiology may be more noticeable.

Methods

Study population

We used data from a hospital-based enhanced surveillance study of children with respiratory disease, as previously described^{34,35}. In brief, children younger than 5 years old who resided in 16 out of the 27 communes of Nha Trang and attended the paediatric ward in Khanh Hoa General Hospital (KHGH) in Nha Trang, central Vietnam, with Acute Respiratory Infection (ARI) were enrolled and offered a suite of additional diagnostics. ARI was defined as Cough and / or difficulty breathing. Khanh Hoa hospital is a tertiary care facility and is the only public hospital for the catchment area of the study. More than 94% of all pediatric ARI admissions are typically enrolled. Upon admission, Nasopharyngeal (NP) samples were taken from patients, nucleic acid was extracted and multiplex-PCR assays were performed in order to detect infection with up to 13 respiratory viruses, including influenza A and RSV. Positive

samples underwent a second, confirmatory PCR test and only individuals who tested positive in both PCRs were included. We use aggregate weekly data, from 5th February 2007 until 4th December 2017. We assumed that an ARI episode, for which Influenza or RSV were detected from the nasopharynx on admission, was caused by the respective pathogen. The dataset excludes neonatal cases under 28 days old.

To inform transmission pathways in the population we used age specific contact-patterns, based on a contact study in the same area, conducted in 2010³⁶. In total 2002 Nha Trang residents of all ages participated in the study. A contact was defined as either skin-to-skin contact or a two-way conversation.

Data analysis

We calculated the correlation between all reported influenza and RSV cases each week using a Pearson's Correlation test.

Assuming no interaction (in susceptibility to or severity of dual infections), we calculated the required annual RSV infection attack rate in order to observe the reported number of dual infections (equations 1-3). We estimate the RSV attack rate rather than the influenza attack rate, as RSV is more consistent year on year (see supplement section 1 for influenza equivalent). Using a negative binomial likelihood with Brent optimization we estimated the RSV reporting rate that would correspond to the maximum likelihood of observing the reported weekly number of dual infections. We then used this estimate of the reporting rate to calculate the annual RSV population attack rate required in order to observe this many coinfecting ARI admissions. The credible intervals for the attack rate were calculated using the Hessian matrix from the optimisation. If the estimated attack rate is high, this may

suggest that influenza and RSV co-infection increase severity (and hence reporting). If the estimated attack rate is low, this could suggest that co-infection is less likely than at random due to competition between the viruses.

$$I_{Dual} \simeq I_{Influenza} * P_{RSV} \quad (1)$$

$$P_{RSV} \simeq I_{RSV} * 1/\gamma_{RSV} / \nu_{RSV} \quad (2)$$

$$AR_{RSV} \simeq I_{RSV} / \nu_{RSV} \quad (3)$$

With parameters: Incidence of reported cases (I), Prevalence of Infection (P), Duration of Infection ($1/\gamma$, 9 days - see Table 1), attack rate (AR) and estimated reporting rate (ν).

Model

We created an age-structured deterministic transmission model for influenza and RSV, allowing for short-term cross-protection (Figure 2C). Individuals are either Susceptible (S), Infectious (I), cross-Protected (P) and Recovered (R) for influenza (INF) and (RSV).

Susceptibles become infected at force of infections λ_{INF} and λ_{RSV} , and move into the I states. They then remain infectious for $1/\gamma_{INF}$ and $1/\gamma_{RSV}$ days and during the infectious period and $1/\rho$ days thereafter they are cross-protected and thus their propensity for heterologous infection is reduced by factor σ , the strength of cross-protection. All age groups are equally susceptible to influenza, but there is reduced susceptibility to RSV in older age groups, determined by parameter τ_i .

The force of infection includes age-specific contact rates derived from a local contact survey³⁶. Modelled age-groups are: 0-1 years (infants), 2 - 4 years (pre-school), 5 - 15 years

(school), 16 - 64 years (adults) and 65 + (older adults). Infection reporting rates vary by age-group and virus, and for RSV reporting rates are increased by a multiplier from 2012 onwards, due to the circulation of a new genotype that has increased the average severity of infection and thus the proportion of reported infections (ON-1)³⁷. There is also a multiplier on the RSV reporting rates for dual infections, allowing them to be reported more frequently, for example because of increased propensity for respiratory disease that would require healthcare seeking (as observed in adults⁴). Model equations are shown in supplement section 3.

We model each season individually, with an initial proportion infected with each virus (v_{INF} and v_{RSV}). For RSV we assume the only immunity at the beginning of the season is the age-specific reduction in susceptibility (leaky immunity), as immunity to reinfection typically lasts less than a year³⁸. Due to infections in previous influenza seasons and potential vaccination, susceptibility to influenza is assumed to decline exponentially at rate η with age (see supplement section 6). This is modelled as non-leaky cross-protection, due to the combination of different exposures. Due to the short-time period modelled (max 66 weeks), we do not include births, deaths or ageing, but instead hold the age-group specific population sizes constant at the levels of 2010. Parameter definitions and values are shown in Table 1.

Parameter	Symbol	Value	Prior	Source
Transmission rate INF	β_{INF}	Fitted	Based on $R_{0,INF}$	See supplement section 4 for calculations
Basic Reproduction Rate Influenza	$R_{0,INF}$	Fitted	Between 1 and 8	26
Transmission rate RSV	β_{RSV}	Fitted	Based on $R_{0,RSV}$	See supplement section 4 for calculations
Basic Reproduction Rate RSV for strain y	$R_{0,RSV,y}$	Fitted	Between 1 and 8	26

RSV age group susceptibility (0-1, 2-4, 5-15, 16-64, 65+)	τ_i	Fixed	1, 0.75, 0.65, 0.65, 0.65	Based on Henderson et al (1979) ³⁹ , see supplement section 5
Infectious period Influenza	$1/\gamma_{INF}$	3.8 days	-	Cauchemez et al (2004) ⁴⁰ Range from published papers: 1 - 4.5 days ⁴⁰⁻⁴³
Infectious period RSV	$1/\gamma_{RSV}$	9 days	-	Weber et al (2001) ³⁸ Range from published papers 6.7-12 days ^{38,44,45}
Strength of cross-protection	σ	Fitted	0 - 1	Assuming competitive ⁴⁶
Duration of cross-protection	$1/\rho$	Fitted	0 - Inf days	
Proportion of each age group infected with Influenza, at the start of the season	$\delta_{INF,s}$	Fitted	0 - 1	
Proportion of each age group infected with RSV, at the start of the season	$\delta_{RSV,s}$	Fitted	0 - 1	
Proportion susceptible to influenza at the start of the season	η_s	Fitted	0 - 1	Exponential function, see supplement section 6 for details
Influenza proportion reported in ages 0-1	κ_{INF}	Fitted	0 - 0.4	
Influenza multiplier for proportion reported ages 2-5 vs 0-1	$\kappa_{INF,m}$	Fitted	0-5	
RSV proportion reported in age group i	$\kappa_{RSV,i}$	Fitted	0-0.4	No additional severity from dual infection ⁴⁷

RSV ON-1 reporting multiplier	$\kappa_{RSV,2012}$	Fitted	1-5	ON-1 clinically more severe ³⁷
Dual infection multiplier on RSV proportion reporting	κ_{Dual}	Fitted	1 - Inf	Based on analysis of expected RSV Attack Rate above.
Overdispersion parameter	k	Fitted	0-Inf	

Table 1: Parameter definitions, values and priors

To capture the annual influenza and RSV epidemics despite regular changes, particularly in the timing of influenza circulation, we defined the annual start of the season as the minimum number of combined RSV and Influenza cases (on a 4 week rolling mean) between the 1st of November and the 1st of May each season. If one or more weeks had the same rolling average, we took the first occurrence within the time window. (Figure 2)

Likelihood

We fitted the model to the age-stratified weekly number of ARI cases with nasopharyngeal carriage of either influenza or RSV using a negative binomial likelihood. To fit the allocation of those cases into influenza, RSV or dual infections we added a multinomial component to the likelihood, resulting in an overall log likelihood of:

$$LL(x|\theta) = \sum_{j=1}^{N=2} \sum_{i=1}^n (NB(\mu_{i,j}, k) + MN(p_{RSV_{i,j}}, p_{Flu_{i,j}}, p_{Dual_{i,j}})) \quad (4)$$

Where x are the reported infections, θ are the parameters, j are the two age groups 0-1 and 2-4, and i are the weeks, with n being the total number of weeks. NB is the likelihood of the observed number of cases being a random draw from a negative binomial distribution with the total number of modelled infections as the mean, μ , and the fitted overdispersion parameter, k . MN is the multinomial likelihood, with p_{RSV} , p_{Flu} and p_{Dual} being the respective probabilities of the infection with influenza, RSV or both, calculated from the ratio of model reported cases.

328 Inference

329 We used parallel tempering to fit the model. This method involves running multiple markov
330 chains simultaneously, with different ‘temperatures’ that place a weighting on the likelihood.
331 Swaps between the chains are then proposed every x (in this case 5) iterations, and accepted
332 with acceptance ratio:

$$333 \quad R = e^{((LL(i) - LL(j)) * (\tau_j - \tau_i))}$$

334 Where

$$335 \quad \tau_i = \frac{1}{T_i}$$

336 For full details of the method see Vousden *et al* (2016)⁴⁸ We ran the parallel tempering
337 algorithm with 12 chains and 450,000 iterations. The initial 250,000 iterations were discarded
338 as burn-in. Accepted samples from the first chain were then thinned to 1 in 10 for analysis.

339 Single pathogen simulations

340 To assess the maximal indirect heterologous effect an intervention against either pathogen
341 (e.g. widespread vaccination) could have in this environment, we assumed that complete
342 absence of one of the viruses. We then calculated the relative change in the number of cases
343 in the pathogen not targeted by the intervention. Estimates are based on model simulations
344 using 1000 posterior parameter samples of the fitted model.

345 Sensitivity analyses

346 We assessed the sensitivity of our estimates of the strength of interaction of influenza and
347 RSV to the prior on the interaction parameter and to the reporting rates of dual infections. We
348 reran the model with a prior on the interaction parameter for strong interaction, using a
349 normal distribution with mean 0.8 and standard deviation of 0.15. In addition, we ran a
350 version of the model where the reporting rate for dual infections and RSV was the same, as it

has been reported that in this setting there is no increased severity of dual infections among hospitalised children⁴⁷.

Ethics

This study was approved by the Institutional Review Boards of the London School of Hygiene & Tropical Medicine (16166 /RR/12988) and the National Institute of Hygiene and Epidemiology in Vietnam (VN01057-28/2015)

Software

All analysis except for the fitting was done in R version 4.0.0. The fitting was done on R 3.4 on AWS ec2 machines. Code is available at https://github.com/NaomiWaterlow/NhaTrang_flu_rsv_interaction

References

1. Lafond, K. E. *et al.* Global Role and Burden of Influenza in Pediatric Respiratory Hospitalizations, 1982–2012: A Systematic Analysis. *PLOS Med.* **13**, e1001977–e1001977 (2016).
2. Shi, T. *et al.* Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015: a systematic review and modelling study. *Lancet Lond. Engl.* **390**, 946–958 (2017).
3. WHO | WHO vaccine pipeline tracker. *WHO* (2016).
4. Zhang, Y. *et al.* Severity of influenza virus and respiratory syncytial virus coinfections in hospitalized adult patients. *J. Clin. Virol. Off. Publ. Pan Am. Soc. Clin. Virol.* **133**, 104685 (2020).

5. Lee, Y. J. *et al.* Non-specific Effect of Vaccines: Immediate Protection against Respiratory Syncytial Virus Infection by a Live Attenuated Influenza Vaccine. *Front. Microbiol.* **9**, 83–83 (2018).
6. Walzl, G., Tafuro, S., Moss, P., Openshaw, P. J. & Hussell, T. Influenza virus lung infection protects from respiratory syncytial virus-induced immunopathology. *J. Exp. Med.* **192**, 1317–26 (2000).
7. Glezen, W. P., Paredes, A. & Taber, L. H. Influenza in Children. *JAMA* **243**, 1345–1345 (1980).
8. Anestad, G. Interference between outbreaks of epidemic viruses. *Scand. J. Infect. Dis.* **39**, 653–654 (1982).
9. Hirsh, S. *et al.* Epidemiological changes of Respiratory Syncytial Virus (RSV) infections in Israel. *PLoS ONE* **9**, (2014).
10. Meningher, T. *et al.* Relationships between A(H1N1)pdm09 influenza infection and infections with other respiratory viruses. *Influenza Other Respir. Viruses* **8**, 422–430 (2014).
11. Gröndahl, B. *et al.* The 2009 pandemic influenza A(H1N1) coincides with changes in the epidemiology of other viral pathogens causing acute respiratory tract infections in children. *Infection* **42**, 303–308 (2014).
12. Casalegno, J. S. *et al.* Impact of the 2009 influenza a(H1N1) pandemic wave on the pattern of hibernal respiratory virus epidemics, France, 2009. *Eurosurveillance* **15**, 2–2 (2010).
13. Mak, G. C., Wong, A. H., Ho, W. Y. Y. & Lim, W. The impact of pandemic influenza A (H1N1) 2009 on the circulation of respiratory viruses 2009-2011. *Influenza Other Respir. Viruses* **6**, e6-10 (2012).
14. van Asten, L. *et al.* Early occurrence of influenza A epidemics coincided with changes in occurrence of other respiratory virus infections. *Influenza Other Respir. Viruses* **10**, 14–26 (2016).

15. Nishimura, N., Nishio, H., Lee, M. J. & Uemura, K. The clinical features of respiratory syncytial virus: Lower respiratory tract infection after upper respiratory tract infection due to influenza virus. *Pediatr. Int.* **47**, 412–416 (2005).
16. Pinky, L. & Dobrovolny, H. M. Coinfections of the respiratory tract: Viral competition for resources. *PLoS ONE* **11**, (2016).
17. Valkenburg, S. A. *et al.* Immunity to seasonal and pandemic influenza A viruses. *Microbes Infect.* **13**, 489–501 (2011).
18. Ascough, S., Paterson, S. & Chiu, C. Induction and Subversion of Human Protective Immunity: Contrasting Influenza and Respiratory Syncytial Virus. *Front. Immunol.* **9**, 323–323 (2018).
19. Hamilton, J. Club cells surviving influenza A virus infection induce temporary nonspecific antiviral immunity.
20. Laurie, K. L. *et al.* Interval Between Infections and Viral Hierarchy Are Determinants of Viral Interference Following Influenza Virus Infection in a Ferret Model. *J. Infect. Dis.* **212**, 1701–1710 (2015).
21. Thongpan, I., Vongpunsawad, S. & Poovorawan, Y. Respiratory syncytial virus infection trend is associated with meteorological factors. *Sci. Rep.* **10**, 10931 (2020).
22. Goka, E., Vallely, P., Mutton, K. & Klapper, P. Influenza A viruses dual and multiple infections with other respiratory viruses and risk of hospitalisation and mortality. *Influenza Other Respir. Viruses* **7**, 1079–1087 (2013).
23. Price, O. H., Sullivan, S. G., Sutterby, C., Druce, J. & Carville, K. S. Using routine testing data to understand circulation patterns of influenza A, respiratory syncytial virus and other respiratory viruses in Victoria, Australia. *Epidemiol. Infect.* **147**, e221 (2019).
24. Meskill, S. D., Revell, P. A., Chandramohan, L. & Cruz, A. T. Prevalence of co-infection between respiratory syncytial virus and influenza in children. *Am. J. Emerg. Med.* **35**, 495–498 (2019).

25. Waterlow, N. R., Flasche, S., Minter, A. & Eggo, R. M. Competition between RSV and influenza: limits of modelling inference from surveillance data. *Epidemics* 100460 (2021) doi:10.1016/j.epidem.2021.100460.
26. Spencer, J. A. *et al.* Epidemiological parameter review and comparative dynamics of influenza, respiratory syncytial virus, rhinovirus, human coronavirus, and adenovirus. *medRxiv* 2020.02.04.20020404 (2020) doi:10.1101/2020.02.04.20020404.
27. Kombe, I. K., Munywoki, P. K., Baguelin, M., Nokes, D. J. & Medley, G. F. Model-based estimates of transmission of respiratory syncytial virus within households. *Epidemics* **27**, 1–11 (2019).
28. McNab, S. *et al.* Changing Epidemiology of Respiratory Syncytial Virus in Australia - delayed re-emergence in Victoria compared to WA/NSW after prolonged lock-down for COVID-19. *Clin. Infect. Dis.* (2021) doi:10.1093/cid/ciab240.
29. Gomez, G. B., Mahé, C. & Chaves, S. S. Uncertain effects of the pandemic on respiratory viruses. *Science* **372**, 1043–1044 (2021).
30. Funk, S., Salathé, M. & Jansen, V. A. A. Modelling the influence of human behaviour on the spread of infectious diseases: a review. *J. R. Soc. Interface* **7**, 1247–56 (2010).
31. Minter, A. *et al.* Estimation of Seasonal Influenza Attack Rates and Antibody Dynamics in Children Using Cross-Sectional Serological Data. *J. Infect. Dis.* (2020) doi:10.1093/infdis/jiaa338.
32. Jayasundara, K., Soobiah, C., Thommes, E., Tricco, A. C. & Chit, A. Natural attack rate of influenza in unvaccinated children and adults: a meta-regression analysis. *BMC Infect. Dis.* **14**, 670 (2014).
33. CDC. Learn about RSV in Infants and Young Children. *Centers for Disease Control and Prevention* <https://www.cdc.gov/rsv/high-risk/infants-young-children.html> (2020).
34. Yoshida, L.-M. *et al.* Population based cohort study for pediatric infectious diseases research in Vietnam. *Trop. Med. Health* **42**, 47–58 (2014).

35. Yoshida, L. M. *et al.* VIRAL PATHOGENS ASSOCIATED WITH ACUTE RESPIRATORY INFECTIONS IN CENTRAL VIETNAMESE CHILDREN. *Pediatr. Infect. Dis. J.* **29**, 75–77 (2010).
36. Waroux, O. L. P. D. *et al.* Predicting the impact of pneumococcal conjugate vaccine programme options in Vietnam. *Hum. Vaccines Immunother.* **14**, 1939–1947 (2018).
37. Yoshihara, K. *et al.* Association of RSV-A ON1 genotype with Increased Pediatric Acute Lower Respiratory Tract Infection in Vietnam. *Sci. Rep.* **6**, (2016).
38. Weber, A., Weber, M. & Milligan, P. Modeling epidemics caused by respiratory syncytial virus (RSV). *Math. Biosci.* **172**, 95–113 (2001).
39. Henderson, F. W., Collier, A. M., Clyde, W. A. & Denny, F. W. Respiratory-Syncytial-Virus Infections, Reinfections and Immunity. *N. Engl. J. Med.* **300**, 530–534 (1979).
40. Cauchemez, S., Carrat, F., Viboud, C., Valleron, A. J. & Boëlle, P. Y. A Bayesian MCMC approach to study transmission of influenza: application to household longitudinal data. *Stat. Med.* **23**, 3469–3487 (2004).
41. Hayden, F. G. *et al.* Use of the Oral Neuraminidase Inhibitor Oseltamivir in Experimental Human Influenza. *JAMA* **282**, 1240–1240 (1999).
42. Chowell, G. *et al.* Characterizing the Epidemiology of the 2009 Influenza A/H1N1 Pandemic in Mexico. *PLoS Med.* **8**, e1000436–e1000436 (2011).
43. Cori, A. *et al.* Estimating influenza latency and infectious period durations using viral excretion data. *Epidemics* **4**, 132–138 (2012).
44. Moore, H. C., Jacoby, P., Hogan, A. B., Blyth, C. C. & Mercer, G. N. Modelling the Seasonal Epidemics of Respiratory Syncytial Virus in Young Children. *PloS One* **9**, e100422–e100422 (2014).
45. Hall, C. B., Douglas, R. G. & Geiman, J. M. Respiratory syncytial virus infections in infants: quantitation and duration of shedding. *J. Pediatr.* **89**, 11–5 (1976).
46. Opatowski, L., Baguelin, M. & Eggo, R. M. REVIEW Influenza Interaction with Cocirculating Pathogens, and Its Impact on Surveillance, Pathogenesis and Epidemic

478 Profile: A Key Role for Mathematical Modeling. *PLOS Pathog.* **14**, e1006770–e1006770
479 (2017).
480 47. Yoshida, L.-M. *et al.* Respiratory syncytial virus: co-infection and paediatric lower
481 respiratory tract infections. *Eur. Respir. J.* **42**, 461–469 (2013).
482 48. Vousden, W. D., Farr, W. M. & Mandel, I. Dynamic temperature selection for parallel
483 tempering in Markov chain Monte Carlo simulations. *Mon. Not. R. Astron. Soc.* **455**,
484 1919–1937 (2016).
485